Table S4. HER3 expression in ovarian cancer at initial diagnosis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **HER3 score** | **0** | **1+** | **2+** | **3+** | **2+/3+** | **1+/2+/3+** |
| High-grade serous carcinoma (N=27) | 1(3.7%) | 9(33.3%) | 6(22.2%) | 11(40.7%) | 17(62.9%) | 26(96.3%) |
| Clear cell carcinoma (N=4) | 0(0.0%) | 1(25.0%) | 0(0.0%) | 3(75.0%) | 3(75.0%) | 4(100.0%) |
| Endometrioid carcinoma (N=5) | 0(0.0%) | 0(0.0%) | 4(80.0%) | 1(20.0%) | 5(100.0%) | 5(100%) |
| Mucinous carcinoma (N=1) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(100.0%) | 1(100.0%) | 1(100.0%) |
| Others (N=3) | 1(33.3%) | 1(33.3%) | 1(33.3%) | 0(0.0%) | 1(33.3%) | 2(66.7%) |
| Total (N=40) | 2(5.0%) | 11(27.5%) | 11(27.5%) | 16(40.0%) | 27(67.5%) | 38(95.0%) |